Reimagining Endometriosis Treatment at the Source
VectorSim is developing a novel therapeutic approach designed to target the molecular drivers of endometriosis — addressing the root biology of the disease, not just the symptoms.
Disease Focus
Endometriosis
Approach
Novel Therapeutic
Stage
Preclinical
The Unmet Need
A Disease That Demands a New Approach
Endometriosis affects approximately 190 million women worldwide, yet the therapeutic landscape has remained fundamentally unchanged for decades. Current treatments are limited to hormonal suppression and surgical intervention — both of which manage symptoms without addressing the underlying disease biology.
Hormonal therapies carry significant systemic side effects, and disease recurrence is common after discontinuation. There has been no new mechanistic class of therapy approved for endometriosis in over a generation.
The disease is driven by aberrant local estrogen production within endometriotic lesions — a fundamental biological vulnerability that remains untargeted by current therapies. This is the gap VectorSim was founded to address.
Therapeutic Strategy
Precision Targeting at the Site of Disease
VectorSim's approach targets key molecular drivers of local estrogen biosynthesis within endometriotic tissue. By intervening at the molecular level, we aim to disrupt the estrogen-dependent growth cycle of endometriotic lesions at its origin.
This targeted approach is intended to offer a fundamentally different risk-benefit profile compared to current systemic hormonal therapies.
Development Path
From Discovery to IND
Lead Design & Selection
Completed
In Vitro Screening
In Progress
In Vivo Proof of Concept
Planned
Toxicology
Planned
IND-Enabling Studies
Planned
Lead Design & Selection
Completed
In Vitro Screening
In Progress
In Vivo Proof of Concept
Planned
Toxicology
Planned
IND-Enabling Studies
Planned
VectorSim is currently advancing its lead candidates through in vitro screening in disease-relevant human endometriotic cell models.
About
About VectorSim LLC
VectorSim was founded on the conviction that endometriosis — a disease affecting nearly 200 million women — deserves a therapeutic approach rooted in modern molecular biology, not decades-old hormonal strategies.
We are a preclinical-stage company advancing a novel therapeutic approach toward clinical development. Our work is grounded in a clear disease thesis, rigorous translational planning, and a commitment to addressing the biological root of endometriosis rather than its downstream symptoms.
Interested in learning more?
We welcome conversations with research collaborators, scientific advisors, and early-stage programs aligned with women's health innovation.
Get in Touch